HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ZOLEDRONIC ACID INJECTION safely and effectively. See full prescribing information for ZOLEDRONIC ACID INJECTION.
ZOLEDRONIC ACID INJECTION, for intravenous infusion
Initial U.S. Approval: 2001
INDICATIONS AND USAGE
Zoledronic acid is a bisphosphonate indicated for:
DOSAGE AND ADMINISTRATION
Infusion given intravenously over no less than 15 minutes:
DOSAGE FORMS AND STRENGTHS
5 mg in a 100 mL ready-to-infuse solution (3)
WARNINGS AND PRECAUTIONS
The most common adverse reactions (greater than 10%) were pyrexia, myalgia, headache, arthralgia, pain in extremity (6.1). Other important adverse reactions were flu-like illness, nausea, vomiting, diarrhea (6.2), and eye inflammation (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
No Current Announcements.
Contact Pfizer Medical
Report an Adverse Event